Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines in Immunocompromised Individuals: A Systematic Review and Meta-Analysis Using the GRADE Framework

Xuan Wang, Katrin Haeussler, Anne Spellman, Leslie E. Phillips, Allison Ramiller, Mary T. Bausch-Jurken, Pawana Sharma, Anna Krivelyova, Sonam Vats, Nicolas Van de Velde
doi: https://doi.org/10.1101/2023.04.05.23288195

ABSTRACT

Introduction Despite representing only 3% of the US population, immunocompromised (IC) individuals account for nearly half of the COVID-19 breakthrough hospitalizations. IC individuals generate a lower immune response following vaccination in general, and the US CDC recommended a third dose of either mRNA-1273 or BNT162b2 COVID-19 vaccines as part of their primary series. Influenza vaccine trials have shown that increasing dosage could improve effectiveness in IC populations. The objective of this systematic literature review and pairwise meta-analysis was to evaluate the clinical effectiveness of mRNA-1273 (50 or 100 mcg/dose) versus BNT162b2 (30 mcg/dose) in IC populations using the GRADE framework.

Methods The systematic literature search was conducted in the World Health Organization COVID-19 Research Database. Studies were included in the pairwise meta-analysis if they reported comparisons of mRNA-1273 and BNT162b2 in IC individuals ≥18 years of age; outcomes of interest were SARS-CoV-2 infection, hospitalization due to COVID-19, and mortality due to COVID-19. Risk ratios (RR) were pooled across studies using random-effects meta-analysis models. Outcomes were also analyzed in subgroups of patients with cancer, autoimmune disease, and solid organ transplant. Risk of bias was assessed for randomized and observational studies using the Risk of Bias 2 tool and the Newcastle-Ottawa Scale, respectively. Evidence was evaluated using the GRADE framework.

Results Overall, 22 studies were included in the pairwise meta-analysis. Compared with BNT162b2, mRNA-1273 was associated with significantly reduced risk of SARS-CoV-2 infection (RR 0.87, 95% CI 0.79–0.96; P=0.0054; I2=61.9%), COVID-19–associated hospitalization (RR 0.83, 95% CI 0.76–0.90; P<0.0001; I2=0%), and COVID-19–associated mortality (RR 0.62, 95% CI 0.43–0.89; P=0.011; I2=0%) in IC populations. Results were consistent across subgroups. Because of sample size limitations, relative effectiveness of COVID-19 mRNA vaccines in IC populations cannot be studied in randomized trials and evidence certainty among comparisons was type 3 (low) and 4 (very low), reflecting potential biases in observational studies.

Conclusion This GRADE meta-analysis based on a large number of consistent observational studies showed that the mRNA-1273 COVID-19 vaccine is associated with improved clinical effectiveness in IC populations compared with BNT162b2.

Introduction

The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in 103 million reported infections and 1.1 million deaths to date in the United States (US) (1). In response to the pandemic, mRNA-1273 (Spikevax®, Moderna, Inc., Cambridge, USA) (2) and BNT162b2 (Comirnaty®, Pfizer/BioNTech, New York, USA/Mainz, Germany) (3), each employing novel mRNA technology, were developed and approved for the prevention of COVID-19 (4). Global phase 2/3 studies demonstrated that both mRNA vaccines given in a 2-dose series were highly efficacious at reducing symptomatic infections and hospitalizations in the immunocompetent population (5; 6).

Although immunocompromised (IC) individuals comprise only approximately 3% of the total US population (7), they account for nearly half of the breakthrough COVID-19 hospitalizations (8). While there is a range of severity across conditions at the population level, adults considered immunodeficient had 2.68-fold greater adjusted odds of being hospitalized with COVID-19 compared with immunocompetent individuals due both to the underlying IC condition and therapies used for treatment (9; 10). In 1 study, use of immunosuppression in patients with autoimmune disease resulted in 1.35-fold (95% confidence interval [CI] 1.29–1.40) greater odds of developing life-threatening COVID-19 (11).

Despite being at increased risk of COVID-19–related morbidity and mortality (10; 12-14), IC individuals and patients receiving immunosuppressive medications were excluded from participating in pivotal trials of mRNA-1273 and BNT162b2 (5; 6). Real-world COVID-19 data indicate that vaccine immune responses are generally impaired in IC populations (9; 15-17) and that vaccine effectiveness, as estimated as the odds of obtaining a positive SARS-CoV-2 test result using multivariate logistic regression models, is lower in IC versus immunocompetent individuals (18). In addition to severe COVID-19, IC populations are at higher risk of prolonged SARS-CoV-2 infection (19–26) and viral evolution (19-22; 24; 27; 28) due to poor humoral responses. These risks are exacerbated by even lower antibody responses to SARS-CoV-2 variants (29–35). IC individuals may also contribute disproportionately to SARS-CoV-2 transmission to household contacts (36). High vaccine effectiveness is therefore critically important for this population and the US Centers for Disease Control and Prevention (CDC) recommended a third dose of either mRNA-1273 or BNT162b2 COVID-19 vaccines as part of their primary series.

Influenza vaccine trials demonstrated that high dose vaccines led to improved immune responses in IC individuals compared with standard dose vaccines and suggested that a high dose vaccine offers greater effectiveness for IC populations (37–42). Although both mRNA-1273 and BNT162b2 employ the mRNA mode of action, the composition of each vaccine is different. For instance, the mRNA dosage and type of lipid nanoparticles used in the delivery system differs between vaccines. The mRNA-1273 primary series contains 100 mcg of mRNA and 50 mcg for the booster (2; 43), whereas BNT162b2 contains 30 mcg of mRNA for each primary and booster dose (3; 44). Observational studies have consistently shown differences between the two mRNA COVID-19 vaccines both in terms of immune response (15) and clinical effectiveness (45–47) in IC populations.

As SARS-CoV-2 transitions from a pandemic to an endemic state, countries are transferring vaccination programs from central government purchasing to their respective national healthcare systems, which is triggering in-depth health technology assessments to recommend the best use of available vaccines in specific populations. Several national immunization technical advisory groups (NITAGs), including the Advisory Committee on Immunization Practices (ACIP) in the US, use the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework for identifying questions relevant to healthcare, selecting outcomes of interest and assessing their importance, evaluating the available evidence, and synthesizing evidence to develop recommendations consistent with considerations of values and preferences of patients and the society in which they live (48; 49).

This present analysis follows the GRADE framework to address the following healthcare question: Is the mRNA-1273 COVID-19 vaccine (50 or 100 mcg/dose) more clinically effective in IC populations compared with the BNT162b2 COVID-19 vaccine (30 mcg/dose)? Accordingly, we performed a systematic literature review and pairwise meta-analysis to compare COVID-19 vaccine effectiveness outcomes among IC individuals given either mRNA-1273 or BNT162b2.

Methods

Search strategy and study selection

We performed a systematic literature review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 framework (50). The main search was conducted in the World Health Organization COVID-19 Research Database on April 14, 2022 and updated on December 19, 2022. Databases searched were MEDLINE, International Clinical Trials Registry Platform, EMBASE, EuropePMC, medRxiv, Web of Science, ProQuest Central, Academic Search Complete, Scopus, and COVIDWHO. The search strategy is presented in Table S1.

View this table:
Table 1. Characteristics of Studies Included in the Meta-Analysis

Clinical trials, observational studies, or any real-world evidence published as manuscripts, letters, commentaries, abstracts, or posters were included if they reported efficacy or clinical effectiveness outcomes in IC individuals ≥18 years of age vaccinated with mRNA-1273 or BNT162b2 within the same study. IC individuals were defined as people with immunocompromising conditions falling into the clinically extremely vulnerable (CEV) groups 1 or 2, which include solid organ transplant, solid and hematological cancers, hemodialysis, poorly controlled human immunodeficiency virus (HIV) infection, and autoimmune conditions requiring immunosuppressive therapy (51). Outcomes of interest were vaccine efficacy or effectiveness against SARS-CoV-2 infection, COVID-19–associated hospitalization, and COVID-19– associated death. Recently published systematic literature reviews on the same topic were cross-checked to ensure relevant articles were included. Studies reporting outcomes in pregnant women, current or former smokers, or physically inactive people; with heterologous vaccination schedule (i.e., mix of mRNA-1273 and BNT162b2); with only safety data; or study protocols or economic models were excluded (Table S2). Two independent reviewers selected studies following a two-level approach; a third reviewer arbitrated conflicts. Titles and abstracts were screened against inclusion criteria in level 1, followed by full-text appraisal of articles not excluded at level 1 against selection criteria in level 2.

View this table:
Table 2. GRADE Summary of Findings Overall

Data extraction and quality assessment

Publication details, study and participant characteristics, vaccine type and vaccination status, at-risk condition, and clinical outcomes were extracted. Risk of bias was assessed in accordance with Cochrane review guidelines (52) using the ROB 2 tool (53) for randomized studies and the Newcastle-Ottawa Scale (54) for observational studies. Evidence was evaluated based on GRADE criteria (48; 49).

Statistical analysis

Random-effects meta-analysis models were used to pool risk ratios (RR) and calculate absolute effects as risk difference (RD) per 100,000 individuals across studies. Inverse variance weights were calculated for individual studies with the DerSimonian-Laird method (55). Chi-square testing to evaluate heterogeneity across studies was performed (56). The I2statistic was estimated (0–100%, 0% meaning no evidence of heterogeneity). Subgroup analysis was performed for patients with cancer, autoimmune disease, and solid organ transplant.

Results

Overview of included studies

Of 5,745 unique items retrieved, we identified 35 studies reporting COVID-19 clinical efficacy or effectiveness outcomes in IC individuals ≥18 years of age who received mRNA-1273 or BNT162b2 in the same study (Figure 1). Thirteen articles were excluded because the population did not meet the inclusion criteria (i.e., participants had immunocompromising conditions not included in CEV groups 1 or 2), 1-dose vaccine regimen data were reported, or the outcome of interest data were not reported in sufficient detail for analysis. Characteristics of all nonrandomized (n=21) and randomized (n=1) studies included in the pairwise meta-analysis are shown in Table 1. Overall, 190,643 and 187,813 patients received mRNA-1273 and BNT162b2, respectively. Studies included mostly US populations (n=15) (18; 45; 47; 57-68), with the remaining trials reporting data on patients from Spain (n=3) (32; 46; 69), Italy (n=1) (70), Singapore (n=1) (71), Switzerland (n=1) (72), and multiple countries (n=1) (73). Specific at-risk and IC conditions included solid organ transplant (n=6) (45; 46; 57; 67; 68; 72), cancer (n=5) (18; 45; 62; 65; 70), hemodialysis (n=3) (32; 59; 66), rheumatologic disease (n=3) (18; 47; 73), multiple sclerosis or other neurological autoimmune disease (n=2) (61; 71), inflammatory bowel disease (n=1) (63), primary immunodeficiency with functional B cell defects (n=1) (64), hematological disorders (n=1) (69), and HIV infection (n=1) (72). Two studies did not specify the IC condition (58; 60). Individuals received ≥2 doses of mRNA-1273 or BNT162b2. Data on 2-dose regimens were considered if reported (n=15) (18; 45; 46; 57; 59; 61; 63-69; 72; 73), otherwise data from 3-or 4-dose regimens (n=7) (32; 47; 58; 60; 62; 70; 71) were used. Of studies reporting data from 2-dose regimens, outcomes were assessed ≥14 days after the second dose (n=13), ≥7 days after the second dose (n=1) (63), and other timepoints (n=1) (66). Timing of outcome assessment relative to the second dose was not specified in 3 studies. Variants of concern were delta (n=6) (18; 45; 46; 65; 67; 69), delta and omicron (n=2) (62; 71), delta and beta (n=1) (59), pre-omicron variants (n=1) (47), and omicron only (n=1) (58). Eleven studies did not directly specify the variant assessed (32; 57; 60; 61; 63; 64; 66; 68; 70; 72; 73).

Figure 1.
Figure 1. PRISMA Flow Diagram.

Searches were first performed on April 14, 2022 followed by an update on December 19, 2022. * Databases searched include ICTRP, EMBASE, EuropePMC, medRxiv, Web of Science, ProQuest Central, Academic Search Complete, Scopus, and COVIDWHO. ** Includes internal documents from Moderna and recently published SLRs. COVID-19, coronavirus disease 2019; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SLR, systematic literature review; WHO, World Health Organization.

Risk of bias assessment found no serious risk of bias for 17 studies (randomized, n=1; nonrandomized, n=16) and serious risk of bias in 5 nonrandomized studies primarily due to the lack of description of comparability between cohorts or adjustment for confounding factors (Table S3; Table S4).

View this table:
Table 3. GRADE Summary of Findings by Population Subgroup
View this table:
Table 4. Summary of Evidence for Outcomes of Interest

SARS-CoV-2 infection (randomized study)

Only 1 and 2 laboratory-confirmed, symptomatic SARS-CoV-2 infections occurred in the BNT162b2 and mRNA-1273 arms, respectively, of a single randomized controlled trial (RCT; RR 2.05, 95% CI 0.19–22.42; RD 499, 95% CI −1,137 to 2,136) (72). The small number of events led to uncertainty around the estimates of effect and no association between mRNA vaccine type and risk of SARS-CoV-2 infection was found in this RCT. Evidence certainty was downgraded from type 1 (high) to type 3 (low) for imprecision and limited evidence (Table 2; Table S4).

SARS-CoV-2 infection (nonrandomized studies)

Of the 17 nonrandomized studies reporting SARS-CoV-2 infection, mRNA-1273 was associated with a statistically significant reduction in the risk of SARS-CoV-2 infection compared with BNT162b2 (RR 0.87, 95% CI 0.79–0.96; P=0.0054; Figure 2). The RD (95% CI) of mRNA-1273 versus BNT162b2 was estimated to be 412 fewer SARS-CoV-2 infections (from 665 fewer to 160 fewer). Heterogeneity between studies may be considered substantial (I2=61.9%). The certainty of evidence was graded as type 4 (very low) for imprecision and indirectness due to varying outcome definitions (Table 2; Table S3).

Figure 2.
Figure 2. Summary of the Clinical Effectiveness Meta-Analysis.

Relative risks of clinical effectiveness outcomes for mRNA-1273 versus BNT162b2 COVID-19 vaccines in IC populations are shown. CI, confidence interval; COVID-19, coronavirus disease 2019; IC, immunocompromised; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Analysis of 4 studies each reporting SARS-CoV-2 infection in patients with cancer (45; 65; 69; 70) found that mRNA-1273 was associated with significantly reduced risk of infection compared with BNT162b2 (RR 0.73, 95% CI 0.57–0.92, P=0.0088; RD −346, 95% CI −598 to −94, P=0.0071). Similar findings were observed in 4 studies assessing patients with autoimmune diseases (RR 0.67, 95% CI 0.52–0.88; P=0.0032; RD −455, 95% CI −1,209 to 298) (47; 61; 63; 71). No association between mRNA vaccine type was found for the 4 studies reporting SARS-CoV-2 infection in solid organ transplant recipients (RR 1.05, 95% CI 0.87– 1.26; RD −93, 95% CI −573 to 386) (45; 57; 67; 68). No evidence of heterogeneity was observed between any of the studies (I2=0% for all subgroups). As in the overall analysis of SARS-CoV-2 infection, the certainty of evidence was graded as type 4 (very low; Table 3).

Hospitalization due to COVID-19

mRNA-1273 was associated with a significantly lower risk of COVID-19–associated hospitalization versus BNT162b2 in the 9 studies included in the overall analysis (RR 0.83, 95% CI 0.76–0.90; P<0.0001; Figure 2). The RD (95% CI) of mRNA-1273 compared with BNT162b2 was estimated to be 60 fewer hospitalizations due to COVID-19 (from 140 fewer to 20 more). No evidence of heterogeneity was observed between studies (I2= 0%). The certainty of evidence for this outcome was type 3 (low) due to inclusion of nonrandomized studies and imprecision (Table 2; Table S3).

In 2 studies reporting hospitalization in patients with cancer (18; 45), mRNA-1273 was associated with a significantly reduced risk of hospitalization compared with BNT162b2 (RR 0.54, 95% CI 0.37–0.79; P=0.0013; RD −585, 95% CI −1,655 to 485). No association between mRNA vaccine type and COVID-19–associated hospitalization was found for the 3 studies each reporting hospitalization in the subgroups of patients with autoimmune diseases (RR 0.97, 95% CI 0.70–1.35; RD −103, 95% CI −1,661 to 1,456) (18; 71; 73) or solid organ transplant (RR 0.91, 95% CI 0.78–1.06; RD −147, 95% CI −816 to 522) (45; 46; 68). No evidence of heterogeneity was observed between any of the studies for the subgroup analysis. The certainty of evidence in all subgroups was graded as type 3 (low; Table 3).

Death due to COVID-19

Of the 4 studies reporting COVID-19–associated mortality (46; 57; 66; 67), mRNA-1273 was associated with a significantly reduced risk of death compared with BNT162b2 (RR 0.62, 95% CI 0.43–0.89; P=0.011; Figure 2). mRNA-1273 was estimated to lead to 56 fewer deaths associated with COVID-19 (from 559 fewer to 446 more) compared with BNT162b2. No evidence of heterogeneity was observed between any of the studies (I2=0%). The certainty of evidence was rated as type 3 (low) due to inclusion of nonrandomized studies (Table 2; Table S3). Grading was reduced for imprecision and increased due to the strong association in RR.

COVID-19–associated death was assessed only in the subgroup of solid organ transplant recipients (46; 57; 67). In these 3 studies, mRNA-1273 was associated with a significantly reduced risk of death compared with BNT162b2 (RR 0.56, 95% CI 0.37–0.84; P=0.0049; RD −3,528, 95% CI −12,002 to 4,945). No evidence of heterogeneity was observed between any of the studies in this subgroup (I2=0%). The certainty of evidence was type 3 (low) due to inclusion of nonrandomized studies as well as imprecision and limited evidence (Table 3).

Discussion

In this systematic review and pairwise meta-analysis of 22 studies, we found that mRNA-1273 was associated with a significantly lower risk of SARS-CoV-2 infection, hospitalization due to COVID-19, and COVID-19–associated mortality compared with BNT162b2 in adults with a broad spectrum of severe immunocompromising conditions. The certainty of this evidence was type 4 (very low) for the SARS-CoV-2 infection outcome and type 3 (low) for the COVID-19– associated hospitalization and death outcomes (Table 4). As all included studies were pairwise comparisons between mRNA-1273 and BNT162b2, the research question was not biased by differences in time period assessed, population, viral variants within each study. When outcomes were assessed in subgroups, mRNA-1273 was associated with significantly lower risk of SARS-CoV-2 infection and COVID-19–associated hospitalization versus BNT162b2 in patients with cancer. Compared with BNT162b2, mRNA-1273 was also associated with a significantly reduced risk of SARS-CoV-2 infection in patients with autoimmune diseases and COVID-19–associated death in solid organ transplant recipients.

IC individuals have a high burden of COVID-19 due to characteristics of their underlying disease or immunosuppressive treatments that impact their ability to mount productive immune responses as well as increased susceptibility to severe COVID-19 (30). Physicians may seek to optimize COVID-19 vaccine type, timing, and number of doses to improve outcomes in IC patients (32). RCTs are ranked highly in the hierarchy of evidence; however, studying comparative efficacy with adequate power would require enrolling a prohibitive number of IC patients. Therefore, the research question can only be assessed using large real-world databases where individual medical and pharmacy information is available.

Limitations of this systematic literature review were that non-English studies were excluded, and publication bias was not assessed in the meta-analysis. Inherent to the GRADE framework, evidence certainty is initially set to either high if the included studies are randomized studies or low if they are observational studies. As all but 1 of the 22 studies included in the pairwise meta-analysis were nonrandomized, the maximum certainty of evidence achievable in this meta-analysis was low despite the high number of observational studies and consistency of results. The pairwise meta-analysis was also limited by inconsistent outcome definitions across studies as well as differences in covariates between studies. For example, the vaccination scheme (2 vs 3 doses; booster) differed between studies, with a mix of primary series (100 mcg vs 30 mcg) and booster (50 mcg vs 30 mcg) pairwise comparisons included in the meta-analysis. Variants of concern changed over time, with risks of hospitalization and death (74) and vaccine effectiveness differing by variant (75). Vaccine effectiveness of 2-dose regimens could only be shown for the delta variant, whereas the omicron variant required a 3-dose schedule. Other sources of bias inherent to observational studies, such as prescribing differences by risk of severe COVID-19 and ability of patients to choose the mRNA vaccine type, could not be accounted for in this meta-analysis. In addition to differences in mRNA dosage between mRNA-1273 and BNT162b2, other differences such as the lipid nanoparticle delivery system and mRNA translation efficiency may also have impacted clinical effectiveness between vaccines.

Our meta-analysis of observational studies showed that mRNA-1273 (50 or 100 mcg/dose) was associated with a significantly reduced risk of SARS-CoV-2 infection, COVID-19-associated hospitalization, and death due to COVID-19 when compared with BNT162b2 (30 mcg/dose) in IC populations. Based on the findings, vaccinating IC individuals in the United States with mRNA-1273 instead of BNT162b2 would prevent an additional 60 and 56 hospitalizations and deaths per 100,000 individuals, respectively. Considering the limited availability of data from RCTs and to provide needed clinical decision-making guidance, our results showed that mRNA-1273 offers better clinical outcomes compared with BNT162b2 in vulnerable IC populations.

Author Contributions

XW and KH designed and performed the systematic literature review and meta-analysis, and critically evaluated the manuscript. AS, LEP, AR, and AK designed and performed the systematic literature review and critically evaluated the manuscript. PS and SV collected data and critically evaluated the manuscript. MTB-J and NVdV conceptualized the article and provided oversight and critical evaluation of the manuscript. All authors contributed to the article and approved the submitted version.

Disclosures

XW, KH, PS, AK, and SV are employees of ICON plc, a clinical research organization paid by Moderna, Inc., to conduct the study. AS is an independent epidemiology consultant/director of Data Health Ltd, which provides health data consultancy services, and was paid by Moderna, Inc., to conduct aspects of this study. LEP is an employee and owner of Data–Driven LLC and AR is a contractor of Data–Driven LLC, a research organization paid by Moderna, Inc. to conduct aspects of this study. MTB-J and NVdV are employees of Moderna, Inc. and hold stock/stock options in the company.

Data Availability

All data produced in the present work are contained in the manuscript.

Funding

This study was funded by Moderna, Inc.

SUPPLEMENTAL MATERIALS

View this table:
Table S1. Databases and Strategies Used for the Systematic Literature Review
View this table:
Table S2. Research Question and PICOS
View this table:
Table S3. ROB Assessment per the NOS Scale for Cohort and Case-Control Studies
View this table:
Table S4. ROB Assessment for RCTs

Acknowledgments

Writing assistance was provided by Erin McClure, PhD, an employee of ICON (Blue Bell, PA, USA) in accordance with Good Publication Practice (GPP3) guidelines, funded by Moderna, Inc., and under the direction of the authors.

References

  1. 1.↵
    National Center for Immunization and Respiratory Diseases (NCIRD) DoVD. COVID Data Tracker Weekly Review: Interpretative Summary for February 10, 2023 [Online] (2023). Centers for Disease Control and Prevention. Available: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html [Accessed February 23 2023].
  2. 2.↵
    SPIKEVAX (mRNA-1273). Full Prescribing Information, ModernaTX, Inc., Cambridge, MA, 2022.
  3. 3.↵
    COMIRNATY (BNT162b2). Full Prescribing Information, Pfizer/BioNTech, New York, NY, 2022.
  4. 4.↵
    Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov (2021) 20:817–838. doi: 10.1038/s41573-021-00283-5.
    OpenUrlCrossRef
  5. 5.↵
    Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med (2020) 383:2603–2615. doi: 10.1056/NEJMoa2034577.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med (2021) 384:403–416. doi: 10.1056/NEJMoa2035389.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Harpaz R, Dahl RM, Dooling KL. Prevalence of Immunosuppression Among US Adults, 2013. Jama (2016) 316:2547–2548. doi: 10.1001/jama.2016.16477.
    OpenUrlCrossRef
  8. 8.↵
    Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin Infect Dis (2022) 74:1515–1524. doi: 10.1093/cid/ciab687.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Ridgway JP, Tideman S, French T, Wright B, Parsons G, Diaz G, et al. Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose. Jama (2022) 328:1559–1561. doi: 10.1001/jama.2022.17811.
    OpenUrlCrossRef
  10. 10.↵
    DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity (2022) 55:1779–1798. doi: 10.1016/j.immuni.2022.09.006.
    OpenUrlCrossRef
  11. 11.↵
    Yadaw AS, Afzali B, Hotaling N, Sidky H, Pfaff ER, Sahner DK, et al. Pre-existing autoimmunity is associated with increased severity of COVID-19: A retrospective cohort study using data from the National COVID Cohort Collaborative (N3C). medRxiv (2023) 2023.2002.2002.23285353. doi: 10.1101/2023.02.02.23285353.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    National Center for Immunization and Respiratory Diseases (NCIRD) DoVD. People with Certain Medical Conditions [Online] (2023). Centers for Disease Control and Prevention. Available: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html [Accessed February 16 2023].
  13. 13.
    Singson JRC, Kirley PD, Pham H, Rothrock G, Armistead I, Meek J, et al. Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 - COVID-NET, 10 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep (2022) 71:878–884. doi: 10.15585/mmwr.mm7127a3.
    OpenUrlCrossRef
  14. 14.↵
    Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, et al. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis (2021) 73:e1964–e1972. doi: 10.1093/cid/ciaa1339.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Stumpf J, Siepmann T, Lindner T, Karger C, Schwobel J, Anders L, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur (2021) 9:100178. doi: 10.1016/j.lanepe.2021.100178.
    OpenUrlCrossRefPubMed
  16. 16.
    Shen C, Risk M, Schiopu E, Hayek SS, Xie T, Holevinski L, et al. Efficacy of COVID-19 vaccines in patients taking immunosuppressants. Ann Rheum Dis (2022) 81:875–880. doi: 10.1136/annrheumdis-2021-222045.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Jena A, Mishra S, Deepak P, Kumar MP, Sharma A, Patel YI, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev (2022) 21:102927. doi: 10.1016/j.autrev.2021.102927.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—nine states, January–September 2021. Morbidity and Mortality Weekly Report (2021) 70:1553.
    OpenUrl
  19. 19.↵
    Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series. EBioMedicine (2021) 67:103355. doi: 10.1016/j.ebiom.2021.103355.
    OpenUrlCrossRefPubMed
  20. 20.
    Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, et al. Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. Clin Infect Dis (2021) 73:e815–e821. doi: 10.1093/cid/ciab072.
    OpenUrlCrossRef
  21. 21.
    Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis (2021) 223:23–27. doi: 10.1093/infdis/jiaa666.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med (2020) 383:2291–2293. doi: 10.1056/NEJMc2031364.
    OpenUrlCrossRefPubMed
  23. 23.
    Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech AM, Lane C, et al. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy. J Infect Dis (2020) 222:1103–1107. doi: 10.1093/infdis/jiaa446.
    OpenUrlCrossRefPubMed
  24. 24.↵
    Khatamzas E, Rehn A, Muenchhoff M, Hellmuth J, Gaitzsch E, Weiglein T, et al. Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host. medRxiv (2021) 2021.2001.2010.20248871. doi: 10.1101/2021.01.10.20248871.
    OpenUrlAbstract/FREE Full Text
  25. 25.
    Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell (2020) 183:1901–1912 e1909. doi: 10.1016/j.cell.2020.10.049.
    OpenUrlCrossRefPubMed
  26. 26.↵
    Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2021) 27:387–389. doi: 10.1016/j.jiac.2020.12.001.
    OpenUrlCrossRef
  27. 27.↵
    Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, et al. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell (2021) 184:2605–2617 e2618. doi: 10.1016/j.cell.2021.03.027.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahun A, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature (2021) 592:277–282. doi: 10.1038/s41586-021-03291-y.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Kwon JH, Tenforde MW, Gaglani M, Talbot HK, Ginde AA, McNeal T, et al. mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients. J Infect Dis (2022) 226:797–807. doi: 10.1093/infdis/jiac118.
    OpenUrlCrossRef
  30. 30.↵
    Parker EPK, Desai S, Marti M, Nohynek H, Kaslow DC, Kochhar S, et al. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Lancet Glob Health (2022) 10:e326–e328. doi: 10.1016/S2214-109X(21)00593-3.
    OpenUrlCrossRef
  31. 31.
    Patyna S, Eckes T, Koch BF, Sudowe S, Oftring A, Kohmer N, et al. Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response. Vaccines (2022) 10: doi: 10.3390/vaccines10040585.
    OpenUrlCrossRef
  32. 32.↵
    Quiroga B, Soler MJ, Ortiz A, Jaravaca Mantecon CJ, Nava Perez N, Serra Martin M, et al. Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study. Clin Kidney J (2022) 15:1856–1864. doi: 10.1093/ckj/sfac169.
    OpenUrlCrossRef
  33. 33.
    Risk M, Hayek SS, Schiopu E, Yuan L, Shen C, Shi X, et al. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. The Lancet Rheumatology (2022) 4:e775–e784. doi: 10.1016/s2665-9913(22)00216-8.
    OpenUrlCrossRef
  34. 34.
    Wieske L, van Dam KPJ, Steenhuis M, Stalman EW, Kummer LYL, van Kempen ZLE, et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. The Lancet. Rheumatology (2022) 4:e338–e350. doi: 10.1016/S2665-9913(22)00034-0.
    OpenUrlCrossRef
  35. 35.↵
    Yang LM, Costales C, Ramanathan M, Bulterys PL, Murugesan K, Schroers-Martin J, et al. Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study. Journal of Clinical Virology (2022) 153:105217.
  36. 36.↵
    Lewis NM, Chu VT, Ye D, Conners EE, Gharpure R, Laws RL, et al. Household Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 in the United States. Clin Infect Dis (2021) 73:1805–1813. doi: 10.1093/cid/ciaa1166.
    OpenUrlCrossRefPubMed
  37. 37.↵
    Caldera F, Hillman L, Saha S, Wald A, Grimes I, Zhang Y, et al. Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial. Inflammatory bowel diseases (2020) 26:593–602. doi: 10.1093/ibd/izz164.
    OpenUrlCrossRefPubMed
  38. 38.
    Colmegna I, Useche ML, Rodriguez K, McCormack D, Alfonso G, Patel A, et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. The Lancet Rheumatology (2020) 2:e14–e23. doi: 10.1016/S2665-9913(19)30094-3.
    OpenUrlCrossRef
  39. 39.
    Hakim H, Allison KJ, Van de Velde LA, Tang L, Sun Y, Flynn PM, et al. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. Vaccine (2016) 34:3141–3148. doi: 10.1016/j.vaccine.2016.04.053.
    OpenUrlCrossRef
  40. 40.
    Halasa NB, Savani BN, Asokan I, Kassim A, Simons R, Summers C, et al. Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients. Biol Blood Marrow Transplant (2016) 22:528–535. doi: 10.1016/j.bbmt.2015.12.003.
    OpenUrlCrossRef
  41. 41.
    McKittrick N, Frank I, Jacobson JM, White CJ, Kim D, Kappes R, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med (2013) 158:19–26. doi: 10.7326/0003-4819-158-1-201301010-00005.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton P, et al. A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. Clin Infect Dis (2018) 66:1698–1704. doi: 10.1093/cid/cix1082.
    OpenUrlCrossRef
  43. 43.↵
    Moderna I. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19): Primary Series for 12 Years and Older [Online] (2022). Cambridge, MA, USA: Moderna, Inc. Available: https://eua.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf [Accessed March 7 2023].
  44. 44.↵
    Pfizer/BioNTech. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA): Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) and Booster Dose for 12 Years of Age and Older [Online] (2022). New York, NY, USA: Pfizer/BioNTech. Available: https://labeling.pfizer.com/ShowLabeling.aspx?id=17675&format=pdf [Accessed March 7 2023].
  45. 45.↵
    Mues KE, Kirk B, Patel DA, Gelman A, Chavers S, Talarico C, et al. Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults in the United States. (2022) doi: 10.1101/2022.05.13.22274960.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    Mazuecos A, Villanego F, Zarraga S, López V, Oppenheimer F, Llinàs-Mallol L, et al. Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Transplantation (2022) 106:1430–1439. doi: 10.1097/tp.0000000000004119.
    OpenUrlCrossRef
  47. 47.↵
    Patel NJ, Wang X, Fu X, Kawano Y, Cook C, Vanni KMM, et al. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study. Seminars in arthritis and rheumatism (2022) 58:152108. doi: 10.1016/j.semarthrit.2022.152108.
    OpenUrlCrossRef
  48. 48.↵
    Schünemann HB, Jan; Guyatt, Gordon; Oxman, Andrew (ed.). (2013). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. The GRADE Working Group.
  49. 49.↵
    Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine (2011) 29:9171–9176. doi: 10.1016/j.vaccine.2011.08.005.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (2021) 372:n71. doi: 10.1136/bmj.n71.
    OpenUrlFREE Full Text
  51. 51.↵
    BC COVID Therapeutics Committee. Practice Tool #2 -Definitions of CEV/Immunosuppressed [Online] (2022). British Columbia, Canada: BC Centre for Disease Control. Available: http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/PracticeTool2_CEVCriteria.pdf [Accessed February 16 2023].
  52. 52.↵
    Higgins JPT SJ, Page MJ, Elbers RG, Sterne JAC. “Chapter 8: Assessing risk of bias in a randomized trial,” in Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022), ed. Higgins JPT, T.J., Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane (2022).
  53. 53.↵
    Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj (2019) 366:l4898. doi: 10.1136/bmj.l4898.
    OpenUrlFREE Full Text
  54. 54.↵
    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Online]. Available: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [Accessed February 16 2023].
  55. 55.↵
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials (1986) 7:177–188. doi: 10.1016/0197-2456(86)90046-2.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    Deeks JJ HJ, Altman DG. “Chapter 10: Analysing data and undertaking meta-analyses,” in Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022), ed. Higgins JPT, T.J., Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane (2022).
  57. 57.↵
    Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl Infect Dis (2021) 23:e13705. doi: 10.1111/tid.13705.
    OpenUrlCrossRef
  58. 58.↵
    Britton A. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance—VISION Network, 10 States, December 2021—August 2022. MMWR. Morbidity and Mortality Weekly Report (2022) 71:
  59. 59.↵
    Butt AA, Talisa VB, Yan P, Shaikh OS, Omer SB, Mayr FB. Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis. Clinical Infectious Diseases (2022) 75:e617–e622. doi: 10.1093/cid/ciac118.
    OpenUrlCrossRef
  60. 60.↵
    Hause AM, Baggs J, Marquez P, Abara WE, Baumblatt JG, Thompson D, et al. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged≥ 12 Years with Presumed Immunocompromise Status—United States, January 12, 2022– March 28, 2022. Morbidity and Mortality Weekly Report (2022) 71:899.
    OpenUrl
  61. 61.↵
    Holroyd KB, Healy BC, Conway S, Houtchens M, Bakshi R, Bhattacharyya S, et al. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes. Multiple sclerosis and related disorders (2022) 67:104079. doi: 10.1016/j.msard.2022.104079.
    OpenUrlCrossRef
  62. 62.↵
    Kelly JD, Leonard S, Hoggatt KJ, Boscardin WJ, Lum EN, Moss-Vazquez TA, et al. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines. Jama (2022) 328:1427–1437. doi: 10.1001/jama.2022.17985.
    OpenUrlCrossRef
  63. 63.↵
    Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology (2021) 161:827–836. doi: 10.1053/j.gastro.2021.05.044.
    OpenUrlCrossRefPubMed
  64. 64.↵
    Pham MN, Murugesan K, Banaei N, Pinsky BA, Tang M, Hoyte E, et al. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. The Journal of allergy and clinical immunology (2022) 149:907–911.e903. doi: 10.1016/j.jaci.2021.11.022.
    OpenUrlCrossRef
  65. 65.↵
    Rooney A, Bivona C, Liu B, Streeter D, Gong H, Khan Q. Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study. Journal of Hematology & Oncology (2022) 15:67. doi: 10.1186/s13045-022-01290-8.
    OpenUrlCrossRef
  66. 66.↵
    Sibbel S, McKeon K, Luo J, Wendt K, Walker AG, Kelley T, et al. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis. J Am Soc Nephrol (2022) 33:49–57. doi: 10.1681/ASN.2021060778.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    Yetmar ZA, Bhaimia E, Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy. Transpl Infect Dis (2022) 24:e13779. doi: 10.1111/tid.13779.
    OpenUrlCrossRef
  68. 68.↵
    Malinis M, Cohen E, Azar MM. Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2021) 21:2916–2918. doi: 10.1111/ajt.16713.
    OpenUrlCrossRef
  69. 69.↵
    Pinana JL, Lopez-Corral L, Martino R, Vazquez L, Perez A, Martin-Martin G, et al. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. J Hematol Oncol (2022) 15:54. doi: 10.1186/s13045-022-01275-7.
    OpenUrlCrossRef
  70. 70.↵
    Pino MS, Cheli S, Perna M, Fabbroni V, Giordano C, Martella F, et al. The national COVID-19 vaccination campaign targeting the extremely vulnerable: the Florence Medical Oncology Unit experience in patients with cancer. European journal of cancer (Oxford, England : 1990) (2022) 170:149–157. doi: 10.1016/j.ejca.2022.04.008.
    OpenUrlCrossRef
  71. 71.↵
    Yeo T, Quek AML, Yong KP, Tye JSN, Ratnagopal P, Soon DTL, et al. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD. Multiple sclerosis and related disorders (2022) 65:104003. doi: 10.1016/j.msard.2022.104003.
    OpenUrlCrossRef
  72. 72.↵
    Speich B, Chammartin F, Abela IA, Amico P, Stoeckle MP, Eichenberger AL, et al. Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clin Infect Dis (2022) 75:e585–e593. doi: 10.1093/cid/ciac169.
    OpenUrlCrossRef
  73. 73.↵
    Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, et al. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open (2022) 8:e002187. doi: 10.1136/rmdopen-2021-002187.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    Sigal A, Milo R, Jassat W. Estimating disease severity of Omicron and Delta SARS-CoV-2 infections. Nat Rev Immunol (2022) 22:267–269. doi: 10.1038/s41577-022-00720-5.
    OpenUrlCrossRefPubMed
  75. 75.↵
    Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med (2022) 20:200. doi: 10.1186/s12916-022-02397-y.
    OpenUrlCrossRefPubMed
Back to top
Posted April 06, 2023.
Download PDF
Data/Code
Email
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines in Immunocompromised Individuals: A Systematic Review and Meta-Analysis Using the GRADE Framework
Xuan Wang, Katrin Haeussler, Anne Spellman, Leslie E. Phillips, Allison Ramiller, Mary T. Bausch-Jurken, Pawana Sharma, Anna Krivelyova, Sonam Vats, Nicolas Van de Velde
medRxiv 2023.04.05.23288195; doi: https://doi.org/10.1101/2023.04.05.23288195
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area